| 0.7156 0.072 (11.14%) | 04-10 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.94 | 1-year : | 1.1 |
| Resists | First : | 0.8 | Second : | 0.94 |
| Pivot price | 0.68  |
|||
| Supports | First : | 0.57 | Second : | 0.47 |
| MAs | MA(5) : | 0.67 |
MA(20) : | 0.72 |
| MA(100) : | 1.03 |
MA(250) : | 1.9 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 30.8 |
D(3) : | 27.8 |
| RSI | RSI(14): 46 |
|||
| 52-week | High : | 7.98 | Low : | 0.57 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ INM ] has closed below upper band by 35.0%. Bollinger Bands are 40.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.72 - 0.72 | 0.72 - 0.73 |
| Low: | 0.65 - 0.66 | 0.66 - 0.66 |
| Close: | 0.71 - 0.72 | 0.72 - 0.72 |
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
Fri, 10 Apr 2026
Income Plays: Is InMed Pharmaceuticals Inc in a long term uptrend - 2026 Market Trends & Verified Momentum Stock Alerts - baoquankhu1.vn
Fri, 03 Apr 2026
InMed Pharmaceuticals Announces ATM Offering Prospectus Filing - TipRanks
Fri, 03 Apr 2026
InMed Pharmaceuticals files prospectus supplement for ATM share sales under amended sales agreement - TradingView
Tue, 31 Mar 2026
[EFFECT] InMed Pharmaceuticals Inc. SEC Filing - Stock Titan
Mon, 30 Mar 2026
InMed Pharmaceuticals Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Mon, 30 Mar 2026
[8-K] InMed Pharmaceuticals Inc. Reports Material Event - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 3 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 10.5 (%) |
| Shares Short | 67 (K) |
| Shares Short P.Month | 120 (K) |
| EPS | -2.89 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.42 |
| Profit Margin | -170.1 % |
| Operating Margin | -258.6 % |
| Return on Assets (ttm) | -49.8 % |
| Return on Equity (ttm) | -97.2 % |
| Qtrly Rev. Growth | -26.3 % |
| Gross Profit (p.s.) | 0.45 |
| Sales Per Share | 1.54 |
| EBITDA (p.s.) | -2.62 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -0.25 |
| PEG Ratio | 0 |
| Price to Book value | 0.2 |
| Price to Sales | 0.46 |
| Price to Cash Flow | -0.29 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|